

## Faculty

Prof. Dr. med. Björn Chapuy  
*Medical clinic for Hematology, Oncology  
and Tumor Immunology | CBF  
Charité - University Medicine  
Berlin, Germany*

Dr. med. Johannes Düll  
*Medical Clinic and Polyclinic II  
University Hospital Würzburg  
Würzburg, Germany*

Prof. Dr. med. Hermann Einsele  
*Medical Clinic and Polyclinic II  
University Hospital Würzburg  
Würzburg, Germany*

Florian Eisele, MD  
*Medical Clinic and Polyclinic II  
University Hospital Würzburg  
Würzburg, Germany*

Professor Andrés J. M. Ferreri, MD  
*University Vita-Salute San Raffaele  
Milan, Italy*

Pieterella Lugtenburg MD, PhD  
*Erasmus MC - Cancer Institute  
Rotterdam, The Netherlands*

Dr. med. Michael Oertel  
*Clinic for Radiotherapy - Radiooncology  
University Clinic Münster  
Münster, Germany*

Prof. Dr. med. Max Topp  
*Medical Clinic and Polyclinic II  
University Hospital Würzburg  
Würzburg, Germany*

Jason Westin, MD, MS, FACP  
*Department of Lymphoma - Myeloma  
Division of Cancer Medicine  
University of Texas MD Anderson  
Cancer Center  
Houston, TX, USA*

Professor Pier Luigi Zinzani  
*Department of Medical and Surgical  
Sciences  
Università di Bologna  
Bologna, Italy*

## Scientific Chair/Host

Dr. med. Johannes Düll

## Venue

Hotel Melchior Park  
Am Galgenberg 49  
97074 Würzburg  
Germany  
Web: <https://t1p.de/melchior>

## With the kind support of our sponsors



## An event of

Academy2 GmbH & Co. KG  
Fürther Straße 33  
90513 Zirndorf, Germany  
Web: <https://cmeducation.de/>  
E-mail: [events@academy2.de](mailto:events@academy2.de)

The contents of this event are designed to be product and service neutral. The organizer confirms, that the scientific chair and the speakers will disclose potential conflicts of interest to the participants. The event is sponsored by the following: Incyte Biosciences Germany GmbH with an amount of 25.000€, Swedish Orphan Biovitrum GmbH, with an amount of 20.000€, AbbVie Deutschland GmbH & Co. KG with an amount of 18.000€, AstraZeneca GmbH with an amount of 10.000€, Gilead Sciences GmbH with an amount of 10.000€, Roche Pharma AG with an amount of 10.000€, BeiGene Germany GmbH with an amount of 10.000€, Bristol-Myers Squibb GmbH & Co. KGaA with an amount of 10.000€. The total expenses of the event amount to 113.000.00€.

# INVITATION & PROGRAM

## Insights in DLBCL: New Horizons 2025

Friday 09.05.2025

Saturday 10.05.2025

Live in Würzburg and online!

Register now!



To get to the registration, click on the button or scan the QR code.

<https://qrco.de/DLBCL2025>

CME-certification is pending

Uniklinikum  
Würzburg



## Welcome letter

Dear colleagues!

Fortunately, the treatment landscape for aggressive lymphoma has undergone a revolution in the last few years. Current therapies have had an impact on first-line therapy. Immunotherapies such as CAR-T-cells and bispecific antibodies are now used as standard of care from the second line onwards. As a result more and more colleagues are using these therapeutic options and thus generating a broad knowledge of the effectiveness and side effects of these therapies.

With our DLBCL congress we are happy to offer a platform where we all can exchange and develop ideas with colleagues and learn from each other. Whether on-site in Würzburg or live online: we are looking forward to a highly informative and exciting event and a lively exchange with you!

Best regards,



Johannes Düll  
Senior physician  
Universitätsklinik Würzburg

## Scientific Program

### Friday, May 9th 2025

- |               |   |
|---------------|---|
| 15:00 - 15:15 | <b>Welcome and introduction</b><br>Prof. Dr. med. Hermann Einsele<br>Dr. med. Johannes Düll   |
| 15:15 - 16:00 | <b>A lot of experience - treatment decisions in the first line - what is important for our patients</b><br>Professor Pier Luigi Zinzani               |
| 16:00 - 16:45 | <b>Methods to confirm success in DLBCL: PET and ctDNA - are we already there where we want? New methods new trial concepts</b><br>Dr. Jason R. Westin |
| 16:45 - 17:15 | <b>CNS Lymphoma - Diagnostic and treatment - state of the art</b><br>Professor Andrés J. M. Ferreri, MD   |
| 17:15 - 17:45 | Coffee break  |
| 17:45 - 18:15 | <b>Radiotherapy in DLBCL - from bridge to CAR-T to consolidation</b><br>Dr. med. Michael Oertel   |
| 18:15 - 19:30 | <b>Immunotherapy in DLBCL long term results- efficacy and toxicities</b><br>Prof. Dr. med. Max Topp   |
| 19:30 - 21:30 | Dinner  |

### Saturday, May 10th 2025

- |               |  |
|---------------|--|
| 9:00 - 10:00  | <b>CAR-T in second line with focus on bridge to CAR-T concepts</b><br>Prof. Dr. med. Björn Chapuy  |
| 10:00 - 10:45 | <b>Bispecs: mono vs combinations: what can we expect?</b><br>Professor Pieterella Lugtenburg, MD, PhD                                      |
| 10:45 - 11:00 | Coffee break   |
| 11:00 - 12:00 | <b>Case studies (second line/third line and beyond) with focus on treatment decision and sequencing of therapies</b><br>Florian Eisele, MD |
| 12:00 - 12:30 | <b>What's hot and what's not? DLBCL-specific highlights of ASH 2024</b><br>Dr. med. Johannes Düll  |
| 12:30         | <b>Conclusion and Farewell</b><br>Dr. med. Johannes Düll   |

Register now!



<https://qrco.de/DLBCL2025>